AstraZeneca, Janssen, Novavax Likely To Be Next ‘Warp Speed’ Vaccines In Phase III
While AstraZeneca’s adenovirus candidate is expected to use Operation Warp Speed’s platform, its start date remains cloaked; the Janssen and Novavax candidates are expected to enter Phase III in September and October, respectively.
You may also be interested in...
The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.
US FDA Commissioner Hahn’s controversial statement about approval before the end of Phase III has at least one taker, which may concern public health observers.
Even as Pfizer and Moderna says their vaccines would need to be stored at very low temperatures, CDC official urges delay on equipment acquisition.